PX1 Research provides laboratory-grade Bronchogen formulated for rigorous in vitro and preclinical investigation into pulmonary surface tension mechanics, bronchial epithelial integrity, and gene expression dynamics. Every batch undergoes strict ISO 17025 third-party validation to guarantee superior chemical purity and analytical consistency for academic and institutional research.
PX1 Research provides laboratory-grade Bronchogen formulated for rigorous in vitro and preclinical investigation into pulmonary surface tension mechanics, bronchial epithelial integrity, and gene expression dynamics. Every batch undergoes strict ISO 17025 third-party validation to guarantee superior chemical purity and analytical consistency for academic and institutional research.
A high-quality Bronchogen surface tension supplier provides analytical-grade Ala-Glu-Asp-Pro peptide synthesized in GMP-compliant facilities with verified chemical purity exceeding 98%. Qualified suppliers must back every lot with independent ISO 17025 third-party Certificate of Analysis (COA) testing, including High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and quantitative chromogenic endotoxin assay data.
For research laboratories evaluating pulmonary biophysics, surfactant layer stability, and bronchial tissue remodeling, acquiring ultra-pure peptides is critical to ensuring reproducible experimental outcomes. PX1 Research delivers USA-manufactured Bronchogen engineered specifically for complex cellular and biophysical assays, eliminating variability caused by synthetic impurities, residual solvents, or bacterial endotoxins.
Bronchogen is a synthetic tetrapeptide comprised of L-amino acid residues: L-alanyl-L-glutamyl-L-aspartyl-L-proline (sequence: Ala-Glu-Asp-Pro, molecular formula: C17H26N4O9, molecular weight: approximately 430.41 g/mol). Classed historically within the family of short peptide bioregulators, its sequence is derived from specific chromatin-interacting peptide fragments implicated in tissue-specific transcriptional control.
At the biomolecular level, Bronchogen's acidic residues (glutamic and aspartic acids) paired with proline introduce specific conformational constraints and charge distributions. Preclinical nuclear magnetic resonance (NMR) and computational modeling indicate that these physical characteristics facilitate selective interaction with the major and minor grooves of genomic DNA within respiratory epithelial lineages.
In cell culture models, the structural stability of the Ala-Glu-Asp-Pro sequence allows it to withstand moderate enzymatic degradation in extracellular media, enabling sustained interaction with nuclear chromatin and intracellular target proteins during longitudinal cell line assays.
Pulmonary surface tension is regulated primarily by the pulmonary surfactant system—a complex lipoprotein complex synthesized by type II alveolar epithelial (ATII) cells. In preclinical models of respiratory dysfunction or mechanical stress, maintaining adequate surface tension reduction at the air-liquid interface is vital to prevent micro-atelectasis and structural collapse.
In vitro studies indicate that Bronchogen exposure modulates the expression profiles of surfactant-associated proteins, particularly Surfactant Protein A (SP-A) and Surfactant Protein B (SP-B). These hydrophobic proteins are essential for the rapid adsorption and spreading of dipalmitoylphosphatidylcholine (DPPC) across the alveolar membrane, directly driving surface tension lowering during cycle expansion.
Furthermore, animal models investigating acute lung injury (ALI) demonstrate that administration of research-grade Bronchogen correlates with preserved interfacial elasticity and reduced minimum surface tension during dynamic Langmuir trough measurements. These biophysical observations suggest that Bronchogen does not act directly as a lipid surfactant itself, but rather as an upstream bioregulatory signal that optimizes endogenous surfactant synthesis and secretion kinetics in cellular systems.
Beyond surface tension mechanics, bronchial epithelial integrity relies on robust cell-cell junction complexes, including tight junctions (zonula occludens-1, occludin) and adherens junctions. Exposure of cultured human bronchial epithelial cells (HBECs) to environmental stressors or inflammatory cytokines typically causes down-regulation of structural barrier proteins.
Preclinical transcriptional profiling shows that Bronchogen modulates chromatin accessibility by binding to specific histone structures and DNA regulatory regions. In vitro data indicate that this interaction promotes the expression of cytoprotective proteins, heat shock proteins, and antioxidant enzymes such as superoxide dismutase (SOD).
Concurrently, research models demonstrate a decrease in pro-inflammatory signal cascades, specifically suppressing the nuclear translocation of NF-kB. Consequently, research groups utilizing all peptides targeting pulmonary architecture frequently incorporate Bronchogen to examine how peptide-DNA interactions attenuate hyper-inflammatory responses and maintain epithelial barrier velocity during oxidative stress assays.
When designing comparative research protocols in pulmonology, cellular regeneration, and tissue remodeling, investigators frequently compare Bronchogen against other low-molecular-weight peptides within our comprehensive research hub.
While Bronchogen specifically targets respiratory epithelium transcription and surfactant protein expression, Chonluten (Glu-Asp-Gly) operates on adjacent bronchial mucosa mechanisms with distinct affinity profiles. Meanwhile, broader immune-modulating peptides like Thymogen (Glu-Trp) focus primarily on T-cell maturation signaling pathways, and systemic cell repair factors such as BPC-157 target focal adhesion kinase and angiogenic pathways rather than respiratory-specific chromatin binding.
Understanding these distinct operational mechanisms allows research facilities to construct precise multi-peptide panels to evaluate synergistic effects on tissue recovery, cellular migration, and biophysical membrane tension stabilization.
Evaluating a high-quality Bronchogen surface tension supplier requires verifying strict manufacturing controls and analytical protocols. Because minor impurities, peptide fragments, or residual synthesis reagents can alter cell viability and biophysical surface tension readings, research institutions must enforce rigorous vendor validation standards.
Key quality indicators for procurement officers and laboratory managers include:
• Synthesis Methodology: Solid-Phase Peptide Synthesis (SPPS) conducted under ISO 9001/GMP-compliant conditions to guarantee precise sequence fidelity.
• Purity Thresholds: High-Performance Liquid Chromatography (HPLC) showing a single major peak with chemical purity consistently strictly verified above 98.0%.
• Mass Verification: High-resolution Electrospray Ionization Mass Spectrometry (ESI-MS) confirming exact molecular weight (430.41 Da ± 0.5 Da).
• Endotoxin Control: Quantitative Limulus Amebocyte Lysate (LAL) testing establishing endotoxin levels below 0.01 EU/mg, preventing artifacts in cell culture and immunological assays.
• Lot Traceability: Complete batch records, analytical documentation, and stability data accessible directly via an online wholesale portal for enterprise lab accounts.
HPLC analysis serves as the primary technique for measuring peptide purity and detecting short-chain deletion sequences. A reliable supplier provides full-spectrum chromatograms using reverse-phase (RP-HPLC) columns, illustrating sharp baseline separation and quantifying total area-under-the-curve (AUC) percentage for the target peak.
Mass Spectrometry complements HPLC by confirming that the peak observed corresponds precisely to the molecular structure of Ala-Glu-Asp-Pro. Mass spectra should exhibit clean parent ion peaks without evidence of adduct formation, deletion fragments, or heavy metal contamination.
Endotoxin contamination represents a major confounding variable in surface tension and pulmonary cell research. Lipopolysaccharides (LPS) cause severe inflammatory artifacting in epithelial cell culture and perturb surfactant lipid monolayers. PX1 Research enforces strict chromogenic LAL testing on every single lot, certifying that researchers receive pristine, non-pyrogenic material suitable for sensitive biophysical measurements.
To preserve the structural integrity of synthetic Bronchogen upon arrival at your facility, standardized storage and handling protocols must be maintained:
• Lyophilized Powder Handling: Lyophilized Bronchogen should be stored at -20°C for short-to-medium term storage, or -80°C for long-term storage, protected from atmospheric moisture and light exposure.
• Reconstitution Media: Reconstitution should be performed using sterile, bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS, pH 7.4), depending on assay parameters.
• Thermal Equilbration: Allow the lyophilized vial to reach room temperature in a desiccator prior to reconstitution to prevent condensation accumulation inside the container.
• Aliquoting and Storage: Once dissolved, split the stock solution into single-use micro-aliquots and store at -80°C. Avoid repeated freeze-thaw cycles, which can induce peptide degradation or aggregation.
• Working Concentrations: Dilute aliquots immediately prior to cell culture application or surface tension assay execution using serum-free medium or specialized physiological buffers.
PX1 Research is dedicated to supporting advanced biochemical, cellular, and biophysical studies by serving as the premier USA-based supplier of high-purity peptides. All products are manufactured in state-of-the-art facilities located within the United States and subject to independent, third-party laboratory verification.
When purchasing Bronchogen from PX1 Research, laboratory researchers gain direct access to lot-specific Certificates of Analysis detailing full HPLC chromatograms, mass spec analysis, and endotoxin reports. Orders ship same-day (Monday through Friday) directly from our California and Arizona fulfillment centers, ensuring minimal transit time and temperature control preservation.
Whether your team is running high-throughput cell culture assays, surface tension biophysics studies, or comparative bioregulatory research, PX1 Research provides the quality control, supply chain transparency, and analytical rigor required for groundbreaking scientific discovery.
What is Bronchogen used for in laboratory research?
Bronchogen (Ala-Glu-Asp-Pro) is a research compound used in vitro and in preclinical animal models to study bronchial epithelial cell dynamics, chromatin interaction, gene expression regulation, and pulmonary surface tension mechanics.
How does Bronchogen influence pulmonary surface tension in preclinical models?
Preclinical data indicate that Bronchogen modulates the gene expression of surfactant-associated proteins (SP-A, SP-B) in alveolar type II cells, which helps maintain the stability and interfacial elasticity of the lipid-protein monolayer at the air-liquid interface.
What analytical methods verify Bronchogen purity at PX1 Research?
PX1 Research verifies Bronchogen quality using third-party ISO 17025 accredited laboratories. Testing includes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for chemical purity (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular weight verification, and chromogenic LAL assays for endotoxin quantification.
What are the recommended storage conditions for lyophilized Bronchogen?
Lyophilized Bronchogen powder should be stored tightly sealed at -20°C for short-term handling or -80°C for long-term stability. Protect vials from light, moisture, and temperature fluctuations.
How should Bronchogen stock solutions be reconstituted for in vitro assays?
Reconstitute Bronchogen using sterile, endotoxin-free bacteriostatic water or PBS (pH 7.4). After reconstitution, create single-use aliquots and store at -80°C to prevent degradation caused by freeze-thaw cycles.
What is the acceptable endotoxin limit for research-grade Bronchogen?
PX1 Research enforces a strict endotoxin threshold of <0.01 EU/mg, verified via quantitative LAL testing. This ensures the peptide will not introduce pyrogenic or inflammatory artifacts into cell culture assays.
How does Bronchogen differ from Chonluten?
Bronchogen is a tetrapeptide (Ala-Glu-Asp-Pro) studied primarily for bronchial barrier integrity and surfactant protein modulation, whereas Chonluten is a tripeptide (Glu-Asp-Gly) targeting related but distinct mucosal gene regulatory targets.
Where does PX1 Research ship Bronchogen from?
PX1 Research ships all orders directly from our USA distribution facilities located in California and Arizona, offering same-day shipping for orders placed Monday through Friday before cut-off times.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.